SILONasdaqPharmaceutical PreparationsFiscal year ends December 31
Silo Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.13−0.05 (-4.24%)
Close on Oct 19, 2026
- Market cap
- $1.24M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$7.27 (−86.54%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Silo Pharma, Inc. saw revenue fall 25.0% to $54.08K over the twelve months to Jun 30, 2026.
Revenue
$54.08K
-25.0% vs. a year earlier
Operating income
-$4.46M
TTM Q2 2026
EPS, diluted
-$7.50
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.24M
- P/E ratio
- –
- Price to sales
- 22.95
- Price to book
- 0.25
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $54.08K
- Net income
- -$4.47M
- EPS, diluted
- -$7.50
- Book value per share
- $4.45
- Diluted shares
- 1M
Fourteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
$54.08K-25.0% YoY
Gross profit
-$7.99K-112.1% YoY
Operating income
-$4.46M
Net income
-$4.47M
EPS, diluted
–
Reported periodTrailing twelve months